DE60135005D1 - Verbindungen und methoden zur wt1-spezifischen immuntherapie - Google Patents

Verbindungen und methoden zur wt1-spezifischen immuntherapie

Info

Publication number
DE60135005D1
DE60135005D1 DE60135005T DE60135005T DE60135005D1 DE 60135005 D1 DE60135005 D1 DE 60135005D1 DE 60135005 T DE60135005 T DE 60135005T DE 60135005 T DE60135005 T DE 60135005T DE 60135005 D1 DE60135005 D1 DE 60135005D1
Authority
DE
Germany
Prior art keywords
methods
polypeptide
compounds
specific immunotherapy
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135005T
Other languages
English (en)
Inventor
Alexander Gaiger
Patricia D Mcneill
Molly Smithgall
Gus Moulton
Thomas S Vedvick
Paul R Sleath
Sally Mossman
Lawrence Evans
A Gregory Spies
Jeremy Boydston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaiger Alexander Seattle Wash Us
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/684,361 external-priority patent/US7115272B1/en
Priority claimed from US09/685,830 external-priority patent/US7329410B1/en
Priority claimed from US09/785,019 external-priority patent/US7144581B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of DE60135005D1 publication Critical patent/DE60135005D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60135005T 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie Expired - Lifetime DE60135005D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/684,361 US7115272B1 (en) 1998-09-30 2000-10-06 Compositions and methods for WT1 specific immunotherapy
US09/685,830 US7329410B1 (en) 1998-09-30 2000-10-09 Compositions and method for WT1 specific immunotherapy
US09/785,019 US7144581B2 (en) 2000-10-09 2001-02-15 Compositions and methods for WT1 specific immunotherapy
US09/938,864 US20030072767A1 (en) 1998-09-30 2001-08-24 Compositions and methods for WT1 specific immunotherapy
PCT/US2001/031139 WO2002028414A1 (en) 2000-10-06 2001-10-03 Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number Publication Date
DE60135005D1 true DE60135005D1 (de) 2008-09-04

Family

ID=27505400

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135005T Expired - Lifetime DE60135005D1 (de) 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie

Country Status (13)

Country Link
US (1) US20030072767A1 (de)
EP (1) EP1328287B1 (de)
JP (2) JP4130359B2 (de)
KR (1) KR100858231B1 (de)
CN (1) CN100545174C (de)
AT (1) ATE402189T1 (de)
AU (2) AU9660801A (de)
CA (1) CA2425072C (de)
DE (1) DE60135005D1 (de)
ES (1) ES2311027T3 (de)
MX (1) MXPA03002983A (de)
NZ (1) NZ540397A (de)
WO (1) WO2002028414A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1103564T3 (da) * 1998-07-31 2009-05-11 Int Inst Cancer Immunology Inc Cancerantigener baseret på tumorsuppressorgen WT1-produkt
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP3728439B2 (ja) * 2001-03-22 2005-12-21 治夫 杉山 Ｗｔ１改変ペプチド
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
CA2893995A1 (en) * 2003-06-27 2005-01-06 International Institute Of Cancer Immunology, Inc. Method of diagnosis of cancer
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
US20080293916A1 (en) * 2004-09-17 2008-11-27 Nec Corporation Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding Peptide
ES2531142T3 (es) * 2005-10-17 2015-03-11 Sloan Kettering Inst Cancer Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
WO2007070907A2 (en) * 2005-12-21 2007-06-28 St. Anna Kinderkrebsforschung Therapeutic compositions
DK1988163T3 (da) 2006-02-22 2012-08-20 Int Inst Cancer Immunology Inc Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme
ES2387999T3 (es) * 2006-03-29 2012-10-05 International Institute Of Cancer Immunology, Inc. ARNsi específico de la isoforma WT1 17AA(-) y uso del mismo
CA2645766A1 (en) * 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
WO2008081701A1 (ja) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
AU2008222061B2 (en) 2007-03-05 2014-03-20 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011059835A2 (en) * 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
US9783821B2 (en) 2011-07-29 2017-10-10 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US10316332B2 (en) 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
CN103797369B (zh) * 2011-09-14 2017-09-19 株式会社癌免疫研究所 抗wt1抗体的测定方法
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
EP2802347B1 (de) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogene wt-1-peptide und verfahren zur verwendung davon
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6250288B2 (ja) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 Ｔ細胞レセプターおよびその利用
JP6770269B2 (ja) * 2015-06-25 2020-10-14 国立大学法人神戸大学 経口腫瘍ワクチン
CA3025648A1 (en) * 2016-05-27 2017-11-30 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (de) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
WO2020032782A1 (ko) * 2018-08-10 2020-02-13 주식회사 유틸렉스 암항원 특이적 cd8+ t 세포의 제조 및 동결보존 방법
CA3113212A1 (en) 2018-09-28 2020-04-02 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
US20230183316A1 (en) 2020-05-12 2023-06-15 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
EP4385519A1 (de) 2021-08-12 2024-06-19 International Institute of Cancer Immunology, Inc. Pharmazeutische zusammensetzung und verfahren zur behandlung oder prävention von krebs
CN115998851A (zh) * 2022-12-28 2023-04-25 四川康德赛医疗科技有限公司 一种个体化mRNA组合物、载体、mRNA疫苗及其应用
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007509A1 (en) * 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
ZA945278B (en) * 1993-07-20 1996-01-19 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
ES2310052T3 (es) * 1998-09-30 2008-12-16 Corixa Corporation Composiciones y metodos para la inmunoterapia especifica de wt1.
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma

Also Published As

Publication number Publication date
US20030072767A1 (en) 2003-04-17
EP1328287B1 (de) 2008-07-23
KR20030081314A (ko) 2003-10-17
EP1328287A4 (de) 2005-09-07
ES2311027T3 (es) 2009-02-01
ATE402189T1 (de) 2008-08-15
WO2002028414B1 (en) 2002-07-18
JP2004510425A (ja) 2004-04-08
CA2425072C (en) 2013-11-26
MXPA03002983A (es) 2004-12-06
KR100858231B1 (ko) 2008-09-12
JP2008154588A (ja) 2008-07-10
EP1328287A1 (de) 2003-07-23
CA2425072A1 (en) 2002-04-11
CN100545174C (zh) 2009-09-30
AU9660801A (en) 2002-04-15
CN1505526A (zh) 2004-06-16
NZ540397A (en) 2008-05-30
WO2002028414A1 (en) 2002-04-11
JP4130359B2 (ja) 2008-08-06
AU2001296608B2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
ATE402189T1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
TW200509967A (en) Compositions and methods for WT1 specific immunotherapy
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
MY136520A (en) Novel compounds
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
TR199700999T1 (xx) Askomisinler.
BR0008307A (pt) Utilização de uma proteìna ompa de enterobactéria ou de um de seus fragmentos, e, composição farmacêutica
DE50110274D1 (de) Arzneimittel zur immuntherapie maligner tumoren
WO2003024302A3 (en) Detection and treatment of cancers of breast
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2003024304A3 (en) Detection and treatment of cancers of the liver
TR200302193T4 (tr) Kombinasyon kemoterapisi.
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
UY26836A1 (es) Pirrolidinas 1,3-disustituidas y 1,3,3-trisustituidas como ligandos del receptor de histamina y sus aplicaciones terapéuticas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CORIXA CORP., WILMINGTON, DEL., US

Owner name: GAIGER, ALEXANDER, SEATTLE, WASH., US